Pular para o conteúdo
Menu
Mix Vale

First preventative vaccine against lung cancer begins human trials in 2026

Jeronimo Santos
Por 3 min de leitura
Compartilhe
Vacina
Foto: Vacina - Foto: Fernando Frazão/Agência Brasil

Universidade of The technology uses a viral vector similar to that of the AstraZeneca vaccine against Covid-19 to deliver DNA that activates an immune response against lung cells with initial mutations. The clinical trial will involve 590 participants in phases 1 and 2, with an initial focus on safety and preliminary signs of efficacy.

Publicidade

Financing of £2 million (around R$13 million) allows the project to move forward, which has already demonstrated positive results in laboratory tests. The vaccine targets the NY-ESO-1 protein, a common marker for pre-tumor changes.

How technology operates in the body

The modified viral vector transports the DNA fragment to the cells. Ao reaches the cell nucleus, the material induces temporary production of the NY-ESO-1 protein.

Publicidade

This protein works as an alert for the immune system. Células T begin to recognize and eliminate lung cells that express the marker before tumor formation.

The mechanism creates specific immune surveillance in the lungs. Preclinical Testes indicated robust activation of cytotoxic T lymphocytes.

Initial audience for clinical trials

The first volunteers will be adults aged 50 to 80 with a history of surgically cured early-stage lung cancer.

People with lung nodules detected in screening and classified as intermediate risk will also participate.

  • Patients operated on with positive margins or compromised lymph nodes
  • Ex-smokers with more than 20 pack-years of consumption
  • Individuals on Low Dose CT Scan Programs for Screening

The selection prioritizes those who are most likely to relapse in the next five years.

Publicidade
Vacina
Vacina – Foto: Ake Ngiamsanguan/ Istockphoto.com

Stages planned for 2026 and 2027

Phase 1 starts with 30 volunteers and tests three different dosages. Researchers monitor adverse reactions for 90 days after each application.

In phase 2, 560 participants receive two doses four weeks apart. Metade of the group receives placebo for comparison.

Primary endpoints include specific T cell activation rate and incidence of serious adverse events. Resultados Phase 1 preliminaries are expected in the second half of 2026.

Epidemiological profile that justifies the development

Lung cancer records around 2.2 million new cases annually worldwide, according to data from Organização Mundial and Saúde.

In Brasil, Instituto Nacional of Câncer estimates 32 thousand new diagnoses for 2025. The disease maintains a five-year survival rate below 20% when diagnosed at an advanced stage.

The incidence increases among non-smokers, especially women, due to exposure to pollutants and genetic factors.

Positioning of Brazilian experts

Oncologists consulted evaluate the project as promising, but emphasize that it is still in its early stages.

The immunological response observed in the laboratory is not always reproduced in humans with the same intensity. Fatores as advanced age and comorbidities may reduce effectiveness.

Defining the final target audience will depend on the results of phases 2 and 3. Active Fumantes, former heavy smokers and carriers of specific genetic mutations are likely candidates.

The vaccine does not replace smoking cessation or CT screening. Ela would be a complement to already identified high-risk groups.

Next steps for the British consortium

Recruitment begins in early 2026 at centers in Reino Unido. Outros European countries must join the study in phase 2b.

If the safety data is positive, phase 3 could involve up to 3,000 participants from 2028. Regulatory approval would only occur after all stages have been completed.

Publicidade

Jeronimo Santos é colaborador da redação do Mix Vale, portal de notícias com cobertura de Brasil e mundo. Produz conteúdo nas editorias de economia e benefícios, com foco em informação de serviço para o leitor brasileiro. Escreve para o portal desde 2016: Formação: Marketing

Notícias relacionadas

Mais lidas

  1. Ciência

    Meteoro no Nordeste: bólido cruza o céu de cinco estados às 21h34 e mobiliza buscas por fragmentos na Paraíba

  2. Caixa Econômica Federal

    Pé-de-Meia paga parcela de R$ 1.000,00 a aprovados no ensino médio de 2026 entre fevereiro e março de 2027

  3. Política

    Com obstrução parcial no intestino, Jair Bolsonaro é internado no hospital DF Star em Brasília

  4. INSS

    Recuperação da senha Gov.br pelo celular exige reconhecimento facial ou código por SMS para o Meu INSS

  5. EUA

    Terremoto em Los Angeles atinge magnitude 4,2 e causa tremores leves em Commerce na madrugada

  6. Matéria Publicitária

    MineMV é o novo jogo grátis de construir com blocos; veja como jogar e liberado para todas as idades

  7. Política

    Regulamentação da escala 5×2 pelo governo encarece cálculo da hora extra a partir de 16 de dezembro

  8. Santa Catarina

    Acidente de trânsito na SC-108 envolve carro e moto e deixa motociclista morto em São Ludgero

  9. Mundo

    Jornalista italiano Corrado Augias morre aos 91 anos; presidente da Itália lamenta a perda

  10. Loterias

    Rendimento de R$ 40 milhões da Mega-Sena 3088 chega a R$ 337 mil por mês no Tesouro Direto